Laboratorios Farmaceuticos Rovi S.A
Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Trypti… Read more
Laboratorios Farmaceuticos Rovi S.A (LABFF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.116x
Based on the latest financial reports, Laboratorios Farmaceuticos Rovi S.A (LABFF) has a cash flow conversion efficiency ratio of 0.116x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($73.37 Million) by net assets ($632.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Laboratorios Farmaceuticos Rovi S.A - Cash Flow Conversion Efficiency Trend (2006–2024)
This chart illustrates how Laboratorios Farmaceuticos Rovi S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Laboratorios Farmaceuticos Rovi S.A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Laboratorios Farmaceuticos Rovi S.A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Federal Agricultural Mortgage Corporation
NYSE:AGM
|
0.060x |
|
Sirius Real Estate Limited
PINK:SRRLF
|
0.037x |
|
LLOYDS METALS AND ENERGY LTD.
NSE:LLOYDSME
|
0.004x |
|
Blackbaud Inc
NASDAQ:BLKB
|
0.682x |
|
Hyundai Elevator
KO:017800
|
0.043x |
|
Chongqing Brewery Co Ltd
SHG:600132
|
0.242x |
|
Newell Rubbermaid Inc.
NASDAQ:NWL
|
0.067x |
|
Quantum Computing Inc
NASDAQ:QUBT
|
-0.007x |
Annual Cash Flow Conversion Efficiency for Laboratorios Farmaceuticos Rovi S.A (2006–2024)
The table below shows the annual cash flow conversion efficiency of Laboratorios Farmaceuticos Rovi S.A from 2006 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $581.54 Million | $138.28 Million | 0.238x | +14.11% |
| 2023-12-31 | $543.49 Million | $113.25 Million | 0.208x | -54.28% |
| 2022-12-31 | $521.38 Million | $237.60 Million | 0.456x | +43.62% |
| 2021-12-31 | $470.98 Million | $149.44 Million | 0.317x | +152.96% |
| 2020-12-31 | $373.70 Million | $46.88 Million | 0.125x | +547.14% |
| 2019-12-31 | $322.39 Million | $-9.04 Million | -0.028x | -194.53% |
| 2018-12-31 | $287.47 Million | $8.53 Million | 0.030x | -68.47% |
| 2017-12-31 | $191.69 Million | $18.04 Million | 0.094x | -62.09% |
| 2016-12-31 | $183.41 Million | $45.53 Million | 0.248x | +39.17% |
| 2015-12-31 | $164.78 Million | $29.39 Million | 0.178x | +22.88% |
| 2014-12-31 | $158.47 Million | $23.00 Million | 0.145x | -29.67% |
| 2013-12-31 | $144.46 Million | $29.82 Million | 0.206x | +33.06% |
| 2012-12-31 | $126.45 Million | $19.61 Million | 0.155x | +39.39% |
| 2011-12-31 | $113.98 Million | $12.68 Million | 0.111x | -45.31% |
| 2010-12-31 | $104.13 Million | $21.19 Million | 0.203x | +51.20% |
| 2009-12-31 | $71.50 Million | $9.62 Million | 0.135x | -26.96% |
| 2008-12-31 | $68.72 Million | $12.66 Million | 0.184x | +731.21% |
| 2007-12-31 | $51.92 Million | $1.15 Million | 0.022x | -92.59% |
| 2006-12-31 | $25.81 Million | $7.72 Million | 0.299x | -- |